Daily Cosmetic Research Analysis

Hypertrophic scar (HS) is a plaque fibrous and indurated dermal lesion that may cause physical, psychological, and cosmetic challenges for patients. Intralesional injection of triamcinolone acetonide (TA) is commonly used in clinical practice, which cause unbearable pain and uneven drug delivery within HS tissue. Herein, we developed a paper battery powered iontophoresis-driven microneedles patch (PBIMNP) for self-management of HS. The high integration of PBIMNP was achieved by incorporating a paper battery as the power source for iontophoresis. The transdermal drug delivery strategy of PBIMNP combined microneedles and iontophoresis techniques, involving "pressing and poking, phase transformation, and diffusion and iontophoresis", which can actively deliver 90.19% drug into the HS tissue with excellent in vitro drug permeation performance. PBIMNP administration effectively reduced the mRNA and protein levels, leading to a decrease in the expression of TGF-β1 and Col I associated with HS formation, demonstrating its efficacy in HS treatment. The microneedles and wearable design endow the PBIMNP as a highly promising platform for self-administration on HS treatment.

Facial fractures significantly impair functions related to respiration, vision, and speech, while also posing long-term cosmetic and psychological challenges. Regional disparities in the burden of facial fractures reflect variations in risk factors, healthcare accessibility, and preventive measures. This study investigates recent causes, trends, and the burden of facial fractures in China and the United States. Utilizing the Global Burden of Disease 2021 dataset, the study analyzed epidemiological data on facial fractures in China and the United States, focusing on age-standardized incidence rates and years lived with disability from 2010 to 2021. Estimated annual percentage changes (EAPC) were calculated to assess trends, while age- and sex-specific analyses provided further insights into population-specific patterns. Additionally, the primary etiologies of facial fractures in both countries were examined. Between 2010 and 2021, the incidence of facial fractures increased in both China and the United States, with a more pronounced rise in China (EAPC: 1.56%) compared to the United States (EAPC: 0.38%). In 2021, the highest incidence in China was observed among males aged 30-34 years, while in the United States, it was among males aged 20-24 years. Males consistently exhibited higher rates than females in both countries. Falls and road injuries were the leading causes of facial fractures in China, whereas falls and mechanical forces were predominant in the United States. The rising incidence of facial fractures in China and the United States highlights the need for targeted preventive strategies tailored to each country's specific risk factors and demographic patterns. These findings underscore the importance of addressing facial fractures as a global public health priority, with implications for policy-making and resource allocation to reduce the burden of these injuries worldwide.

BACKGROUND: Collagen is currently a widely used injectable filler material. Due to the complexity and specificity of the infraorbital structure and function, it undergoes various aging changes earlier in the facial aging process. Additionally, continuous exposure to Ultraviolet (UV) leads to photoaging of the skin. In this study, we utilized type I and type III composite collagen as a filler material for injecting the infraorbital region of the human face and the dorsal region of a nude mouse skin photoaging model to assess its effectiveness and safety. OBJECTIVE: To assess the effectiveness of type I and type III composite collagen in treating age-related changes in the human infraorbital area, as well as in a nude mouse model of skin aging. METHODS: A total of 36 patients with infraorbital aging were enrolled to receive type I and type III composite collagen injections. The improvement of infraorbital aging was assessed at pre-injection, immediate post-injection, 1 week, 4 weeks, and 12 weeks. Additionally, nude mice photodamaged models were prepared and collagen injections were administered to treat photodamaged skin. The therapeutic efficacy was assessed by gross view, histological staining, gene expression analysis, and ELISA assay. RESULTS: Type I and Type III composite collagen injection can immediately fill depressed areas. However, one week after the injection, the collagen dehydrates and contracts, causing the material to be absorbed by the tissues and resulting in a slight regression of the filling effect. After one month, some of the collagen has degraded, with most of it degrading after three months. Additionally, in treating photoaging, type I and type III composite collagen has a more pronounced therapeutic effect on photoaging and demonstrates better results in collagen regeneration, inflammation reduction, and melanin control. CONCLUSION: Type I and Type III composite collagen demonstrates superior efficacy and safety in addressing infraorbital aging and photoaging in nude mice skin, making it a more favorable choice as an injection material. LEVEL OF EVIDENCE II: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors   www.springer.com/00266 .